Indeed, by using canakinumab, a selective antagonist of interleukin-1b in the CANTOS Study on post-myocardial infarction patients, a clear benefit in cardiovascular risk was associated with a highly significant (-35–40%) reduction of hs-CRP [ 10 ].
← all excerpts
Statins and C-reactive protein: in silico evidence on direct interaction.
1
—
—